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The specificity of phage testing for MAP – where might it fit into the diagnostic armoury? 1 
Abstract 2 
The current individual tools available for the diagnosis of Johne’s disease are far from suitable to tackle 3 
this endemic disease. Culture, PCR and ELISA tests, when used together can be useful in managing the 4 
disease in the later stages of infection at a herd level. They are, however, ill-suited to detecting the 5 
causative agent M. avium subsp. paratuberculosis (MAP) at the early stages of infection and at an 6 
individual level. Phage technology offers another tool in the attempt to better manage and control 7 
this disease. Phage-technology has been demonstrated to rapidly and sensitively detect and 8 
specifically identify viable MAP in the milk and blood of cattle. Although in relatively-early stages of 9 
development, phage technology offers a strong addition to the armoury of tests used to detect MAP 10 
in blood and milk, and may go on to be part of ongoing control measures to reduce the burden of 11 
disease to farmers and veterinarians. 12 
 13 
Introduction - Johne’s disease  14 
Mycobacterium avium subspecies paratuberculosis (MAP) is the causative agent of Johne’s 15 
disease; a chronic infectious granulomatous enteritis of ruminants that is endemic in the UK as well as 16 
many countries worldwide.9, 16 As well as being a serious disease from an animal health perspective, 17 
Johne’s disease also places a significant economic burden on farmers.  18 
There are generally four stages of infection for Johne’s disease, which often span several 19 
years: silent, sub-clinical, clinical and advanced.29 Shedding of MAP cells in faeces can occur during the 20 
subclinical stages of infection, resulting in transmission on farm via the faecal oral route. MAP can also 21 
be shed into the milk of infected animals leading to transmission to newly born animals.  Whatever 22 
the route of transmission, it is believed that initial MAP-infection occurs within the first few days of 23 
life, but clinical signs often do not appear until animals reach 3–4 years of age.24 This long incubation 24 
period before Johne’s disease becomes detectable using conventional tests makes effective control 25 
schemes difficult to implement. 26 
 27 
Tried and tested: current tools for diagnosing Johne’s disease 28 
Although classical laboratory culture of MAP is considered the gold standard method of 29 
detection, in practice it is very difficult to perform because MAP is a slow growing organism that is 30 
both difficult and expensive to culture. It can take over 16 weeks to culture the bacterium on 31 
laboratory media and there are high failure rates due to the high risk of contamination by faster 32 
growing organisms.30 To counter this problem, samples such as milk, faeces or tissue biopsies are 33 
decontaminated using chemicals, but these can also affect the viability of the MAP cells in the sample, 34 
thus reducing the sensitivity of culture further.5 Not only does this inability to routinely culture MAP 35 
make the gold standard diagnostic test impractical, it also means that fundamental aspects of the 36 
pathophysiology of Johne’s disease are not well understood, which hinders the development of 37 
control programmes.  38 
There are a range of immunological-based diagnostics that have been developed to diagnose 39 
Johne’s disease. There are many commercial and in-house enzyme-linked immunosorbent assays 40 
(ELISA) to detect anti-MAP antibodies in bovine milk, serum or plasma.  However there can be issues 41 
with cross-reactions occurring if the animals have been exposed to other pathogenic or environmental 42 
mycobacteria which may result in false-positive results.23 Another issue identified is that depending 43 
on the age and stage of infection, sensitivity of detection can be as low at 2 % in calves to 55 % in older 44 
cattle.11, 12 Poor sensitivity of ELlSA tests remains a significant problem and is an unavoidable 45 
consequence of the chronic nature of the disease. Since commercial ELISA tests are generally only 46 
capable of routinely diagnosing Johne’s disease in animals at the later stages of infection, or only 47 
during the very late stages of the subclinical phase of infection, they are not really sensitive enough 48 
to be used on an individual animal basis to reliably confirm infection. Most control programmes test 49 
herds annually,23 however to compensate for the lack of sensitivity, and the fact that antibody levels 50 
in infected animals are known to fluctuate, quarterly testing of individual animals is often carried out, 51 
with the pattern of positive test results being used to classify the infection risk status of an animal. 52 
Despite this limitation, ELISA tests are routinely used as part of disease management programmes as 53 
the high-throughput format and low cost per sample means herds can be screened very quickly and 54 
simply. In addition, ELISAs can be prognostic indicators for reduced milk yield or faecal shedding.15  55 
Molecular detection methods have been developed for the detection of MAP based on 56 
detection of signature DNA sequences by PCR amplification (or other nucleic acid amplification 57 
technologies) that enables the rapid and accurate detection of these bacteria in a variety of matrices. 58 
The most commonly used genetic target is the IS900 insertion element found in multiple copies in the 59 
MAP genome and is considered to be unique to MAP, although the rare occurrence of IS900-like 60 
sequences have been reported in the literature. 6, 7 The fact that IS900 is found in multiple copies within 61 
the MAP genome makes it an ideal signature sequence as the PCR-based detection will be more 62 
sensitive than tests that target single copy genetic elements.21  63 
PCR-based detection is often used when MAP is present in matrices such as faeces or milk to 64 
overcome the problems associated with direct culture described previously.  However these matrices 65 
also contain many PCR inhibitors.  Hence, accurate and sensitive detection of mycobacterial DNA by 66 
PCR relies on both efficient lysis of the bacilli and DNA purification to remove PCR inhibitors and 67 
concentrate DNA.10 Efficient lysis is one of the biggest problems when using direct PCR to detect 68 
mycobacterial DNA because mycobacteria have a very thick cell wall, which make traditional lysis 69 
methods very inefficient, thus reducing the sensitivity of any PCR-based detection event. Where 70 
experimentally, nucleic acid amplification technologies can be shown to specifically and sensitively 71 
detect MAP, the sample preparation and DNA lysis steps are often inefficient, reducing the power of 72 
these technologies. Therefore direct PCR-based detection often require the MAP cells to be present 73 
in high concentrations but the reliability of such methods is confounded by the fact that the 74 
concentration of MAP cells in a sample also fluctuates and is very much dependant on the stage of 75 
infection and bacterial shedding levels.2  76 
 77 
A new approach: Phage Technology 78 
Bacteriophage are viruses that infect bacteria and they will only successfully replicate within 79 
a viable host.  Like all viruses they identify their correct host cells by binding to specific structures 80 
(receptors) on the outside of the bacterial cells.  Once bound, phage inject their own DNA into the 81 
bacterial cell and then take over its machinery to make many copies of themselves before finally 82 
producing enzymes that break down the cell wall and cause the cell to break open,  releasing new 83 
phage particles into the environment (Table 1).  Phage have been used for many years to rapidly detect 84 
different bacterial pathogens, including members of the Mycobacterium genus.20 Several different 85 
phage-based detection assays have been described, such as genetically engineered reporter-phage 86 
that produce a fluorescent or bioluminescent signal when they infect their host cells, or phage binding 87 
to host cells can be detected using physical methods such as plasmon resonance-based spectrometry 88 
(for a full review see Schofield et al., 2012).20 However more recently the detection of mycobacteria 89 
using bacteriophage amplification technology has been developed where the natural life cycle of the 90 
phage is exploited to detect its bacterial host.  91 
Bacteriophage amplification technology has been exploited to detect a range of mycobacteria. 92 
One of the original uses that was commercialised was to detect M. tuberculosis -the causative agent 93 
of tuberculosis (TB) - in human sputum samples.1 The assay was a low cost and simple petri-dish based 94 
test that enabled mycobacteria to be detected within 48 h (for review see Rees & Botsaris, 2012).18 To 95 
develop this assay a broad spectrum bacteriophage, D29, was used which is capable of detecting a 96 
wide range of mycobacteria, including pathogenic and non-pathogenic species. The ability of the assay 97 
to detect many strains, led to the phage amplification assay being applied in the agricultural and food 98 
sectors. However, the broad host range of phage D29 was both an advantage and disadvantage where 99 
in human clinical samples, mycobacteria in the sputum would be treated in the same way regardless 100 
of what species was present. However in food and agriculture settings, many other mycobacterial 101 
species, both pathogenic and environmental may be present in the samples. This results in the 102 
detection of a range of mycobacteria not of interest reducing the specificity of the assay in this plate 103 
based format. Thus the assay was further developed to be able to specifically identify MAP by 104 
combining the phage assay with the IS900 PCR, where the plaques formed on the plates were picked 105 
and screened for these MAP-specific DNA sequences.22 This assay was subsequently used to detect 106 
MAP in a range of matrices including, milk, cheese, infant powdered formula and blood.3, 4, 25 There is 107 
great difficulty in assessing the sensitivity and specificity of any new diagnostic test especially in the 108 
absence of a gold standard. However Botsaris et al,3 had demonstrated that using the phage-PCR 109 
assay, one could accurately predict with a sensitivity of 90 % and specificity of 99 % when a bulk tank 110 
milk sample was positive for MAP based on the number of plaques. Most recently this assay has been 111 
used to detect viable MAP cells in retail milk, where viable MAP cells were detected in 10 % of 112 
pasteurised milk in England.8 However this technology is still reliant on classic microbiological methods 113 
and techniques, which are not particularly suitable for high-throughput samples. 114 
This phage technology has now advanced to a single tube format (Actiphage®, PBD Biotech), 115 
which is more sensitive than the original phage amplification assay27 and suitable for use on a large 116 
number of samples and relies on the four characteristics for phage technology (Table 1). The 117 
Actiphage® assay again relies on the use of bacteriophage, however there is no need for plating or 118 
incubation with fast growing mycobacteria. This assay essentially uses the phage’s ability to lyse 119 
mycobacteria resulting in the efficient release of genomic mycobacterial DNA (Fig. 1). The limitations 120 
of the original phage assay, where plaques were picked and scrutinised for signature DNA sequences,  121 
are negated using this new technique, as a simple PCR or nucleic acid amplification event is carried 122 
out directly on the sample to detect signature MAP DNA sequences. The presence of other 123 
mycobacteria or other bacteria does not affect the assay, as specificity of the assay is all predicated 124 
on the amplification method used (Fig. 2).  125 
The data generated using the phage assay has demonstrated that viable mycobacteria can be 126 
present in the blood of cattle before reaching the latter stages of infection,25, 26 where viable MAP cells 127 
detected in cattle were  either inconclusive or negative by milk and serum ELISA in both naturally and 128 
experimentally infected cattle. Indeed a recent study in France has demonstrated that MAP can be 129 
found in the blood of calves from a Johne’s infected at less than one month of age.17 However it is 130 
difficult to validate a new test for a disease such at Johne’s, where there is no appropriate gold 131 
standard and as such a detection event would be seen as a false positive when compared to the 132 
insensitive ELISA or culture, thus raising questions about the specificity of the assay, whereas a 133 
detection event can only happen in certain circumstances (Table 1). Here a larger study is needed 134 
where further data are required to understand the performance of the phage assay in a wider range 135 
of samples. In the absence of a Gold Standard, other statistical approaches would be required such as 136 
Bayesian analysis, to begin to predict the performance of phage technology as a diagnostic.28 These 137 
data however, may also provide a tool to delve into the complexities of Johne’s disease to ask novel 138 
questions about the pathophysiology of infection, ideally resulting in more information for the control 139 
of this disease.   140 
 141 
A new tool in the armoury? 142 
 Overall, current diagnostic assays for MAP based on serology or faecal testing have poor 143 
sensitivities and cannot detect early stages of infection, therefore there is need to find new diagnostic 144 
markers for early infection detection and disease stages.13 DNA amplification technologies, when 145 
applied in the right format have the potential to be both specific and sensitive, however processing 146 
steps required for efficient DNA amplification are not currently suitable to make the most of the ability 147 
of PCR to detect very low levels of DNA. On an individual cow basis, where an ideal approach would 148 
be  to use serological assays to screen herds for the presence of Johne’s disease, then to use a more 149 
sensitive and robust tool that has the specificity of PCR, but with an improved sensitivity, allow 150 
detection of Johne’s disease at a much early stage of infection in individual animals, thus giving 151 
veterinarians and farmers another tool to control Johne’s disease. 152 
 The ability to rapidly detect and specifically identify mycobacteria responsible for infections 153 
has been very difficult to achieve due the slow growing, fastidious natures of organisms such a MAP. 154 
Phage technology has opened to the door to not only detecting these organisms far quicker than 155 
traditional culture, but also allows novel aspects of the pathophysiological nature of infection to be 156 
studied and understood to fully comprehend diseases just as Johne’s disease. Phage technology is an 157 
attractive new tool which has the potentially to be used in combination with existing technologies and 158 
management schemes to improve and reduce the burden of Johne’s disease on farmers and 159 
veterinarians.  160 
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Key Points 164 
Novel detection methods are needed to control Johne’s disease. 165 
Current diagnostics for Johne’s disease are ill-suited for early detection or on an individual animal 166 
basis. 167 
Phage technology can rapidly, sensitively and specifically detect M. paratuberculosis is blood and milk 168 
Phage technology may be used as another tool in the armoury to tackle Johne’s disease.   169 
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Fig 1. Bacteriophage lysis 280 
 281 
The efficient lysis of bacteria caused by bacteriophage (white arrows). Figure adapted from Roach & 282 
Debarbieux, 2017).19  283 
Fig 2. Schematic of Actiphage® Assay 284 
 285 
Diagram shows the stages of receiving a biological sample, to results. 1. Delivery of sample to the 286 
laboratory, 2. Processing at a central facility, 3. Isolation of peripheral blood mononuclear cells 287 
where mycobacteria are present, 4. Add phage for mycobacteria to sample, 5. Allow phage to infect 288 
any mycobacteria present in the sample, 6. Isolate DNA after cell lysis, 7. Perform DNA amplification 289 
of signature MAP DNA.  290 
 291 
 292 
 293 
  294 
Table 1. Steps required by phage to enable a successful detection event 295 
PHAGE REQUIREMENTS 
 
BINDING 
Phage will only bind to specific bacterium. Here phage D29 will ONLY 
bind to Mycobacterium and no other bacteria 
REPLICATION 
This will only occur inside a VIABLE host, where phage will hijack their 
bacterial hosts machinery and replicate 
LYSIS 
 
Specific enzymes are made when the phage is ready to break open 
their host cell 
DNA RELEASE 
 
This DNA is efficiently released from inside the cell and a species 
specific PCR is  carried out to confirm the identity of the mycobacteria 
present 
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